What did Raymond James do on Feb 26 2026 for ACHC analyst rating?

Raymond James maintained an **Outperform** rating on Acadia Healthcare (ACHC) on February 26, 2026. The firm cited that the 2026 guide was better than feared and pointed to a management change as a positive factor.

Did Raymond James set a new ACHC price target with the rating change?

No. The Raymond James note maintained Outperform but did not publish a new ACHC price target in the StreetInsider report. Lack of a new target limits immediate valuation clarity for investors.

How should investors interpret the maintained Outperform in light of company guidance?

Investors should see the maintained Outperform as cautious optimism tied to 2026 guidance of **$3.37 billion–$3.45 billion**. It suggests potential relative strength, but execution and Medicaid headwinds remain key risks.

What is Meyka AI’s view and grade for ACHC after the rating action?

Meyka AI rates **ACHC** with a grade of **B**. This grade reflects benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Analyst Ratings

Raymond James Maintains Outperform on Acadia Healthcare (ACHC) Feb 26 2026

ByDanny Kontos February 27, 2026February 27, 2026

Raymond James on February 26, 2026 maintained an Outperform rating on Acadia Healthcare Company, Inc. (ACHC). The firm told clients that the 2026 guide was “not as bad as feared” and highlighted a management change as a positive catalyst. This note is the key recent move in ACHC analyst rating coverage and comes after Q4 2025 results and new 2026 guidance. We examine Raymond James’ rationale, the market reaction, and what the maintained Outperform means for investors holding ACHC stock.